Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer

Cell Cycle

Volumn 12, Issue 11, 2013, Pages 1679-1687

  Bisso, Andrea ^a,b,f   Faleschini, Michela ^a   Zampa, Federico ^a   Capaci, Valeria ^a   Santa, Jacopo De ^a   Santapia, Libero ^c   Piazza, Silvano ^a   Cappelletti, Vera ^d   Daidone, Mariagrazia ^d   Agami, Reuven ^e   Del Sal, Giannino ^a,b  

^a Laboratorio Nazionale CIB   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Translational Research Unit   (Italy)

^d IRCCS   (Italy)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

ATM; BRCA1; BRCAness; Breast cancer; DNA damage response; MicroRNA; PARP inhibitors

Indexed keywords

ANTAGOMIR; ATM PROTEIN; HISTONE H2AX; MICRORNA; MICRORNA 181A; MICRORNA 181B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA CONTENT; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; GENE EXPRESSION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ONCOGENE; PRIMARY TUMOR; TRIPLE NEGATIVE BREAST CANCER;

ATAXIA TELANGIECTASIA;

EID: 84878523316     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24757     Document Type: Article

References (49)

1. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-42; PMID:17136094; http://dx.doi.org/10. 1038/nature05327
2. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70; PMID:15829956; http://dx.doi.org/10. 1038/nature03482
3. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene 2006; 25:5906-11; PMID:16998505; http://dx.doi.org/10.1038/sj.onc.1209873
4. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12:68-78; PMID:22193408; http://dx.doi.org/10.1038/nrc3181
5. Mueller CR, Roskelley CD. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 2003; 5:45-52; PMID:12559046; http://dx.doi.org/10.1186/bcr557
6. Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triplenegative breast cancer. Oncogene 2008; 27:2501-6; PMID:17982490; http://dx.doi.org/10.1038/sj.onc.1210885
7. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564-9; PMID:10749912; http://dx.doi.org/10.1093/jnci/92.7.564
8. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol 2003; 23:2225-38; PMID:12640109; http://dx.doi.org/10.1128/MCB.23.7. 2225-2238.2003
9. Song L, Lin C, Wu Z, Gong H, Zeng Y, Wu J, et al. miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase. PLoS ONE 2011; 6:e25454; PMID:21980462; http://dx.doi.org/10.1371/ journal.pone.0025454
10. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA. ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci USA 2010; 107:1506-11; PMID:20080624; http://dx.doi.org/10.1073/pnas.0907763107
11. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 2011; 3:279-90; PMID:21472990; http://dx.doi.org/10.1002/emmm.201100136
12. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011; 41:210-20; PMID:21195000; http://dx.doi.org/10.1016/j.molcel. 2010.12.005
13. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814-9; PMID:15510162; http://dx.doi.org/10.1038/ nrc1457
14. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012; 33:2007-17; PMID:22822097; http://dx.doi.org/10.1093/carcin/bgs232
15. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012; 12:587-98; PMID:22918414; http://dx.doi.org/10.1038/nrc3342
16. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nature reviews. Clin Oncol 2010; 7:702-7
17. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481:287-94; PMID:22258607; http://dx.doi.org/10.1038/nature10760
18. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10:704-14; PMID:19763153; http://dx.doi.org/10.1038/nrg2634
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002
20. Brodersen P, Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 2009; 10:141-8; PMID:19145236; http://dx.doi.org/10.1038/nrm2619
21. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131:1109-23; PMID:18083101; http://dx.doi.org/10.1016/j. cell.2007.10.054
22. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, et al. miR-10b, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med 2012; 4:1214-29; PMID:23125021; http://dx.doi.org/10.1002/emmm.201201483
23. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A MicroRNA targeting dicer for metastasis control. Cell 2010; 141:1195-207; PMID:20603000; http://dx.doi.org/10.1016/j. cell.2010.05.017
24. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-61; PMID:16461460; http://dx.doi.org/10. 1073/pnas.0510565103
25. Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, et al. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 2011; 6:e20980; PMID:21738599; http://dx.doi.org/10. 1371/journal. pone.0020980
26. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14:2348-60; PMID:18812439; http://dx.doi.org/10.1261/rna.1034808
27. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9:759-69; PMID:18813293; http://dx.doi.org/10.1038/nrm2514
28. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11:220-8; PMID:20177397; http://dx.doi.org/10.1038/nrm2858
29. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286:1162-6; PMID:10550055; http://dx.doi. org/10.1126/science.286. 5442.1162
30. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
31. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275-81; PMID:18250347; http://dx.doi.org/10.1200/JCO.2007.14.4147
32. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395-9; PMID:22495314
33. Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011; 30:1470-80; PMID:21102523
34. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP. TGF-? upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 2013; 123:150-63; PMID:23241956; http://dx.doi.org/10.1172/JCI64946
35. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39:493-506; PMID:20797623; http://dx.doi. org/10.1016/j.molcel.2010.07.023
36. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29:1787-97; PMID:20023698; http://dx.doi.org/10.1038/onc.2009.468
37. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27:1859-67; PMID:17194750; http://dx.doi.org/10.1128/MCB.01395-06
38. Ji J, Yamashita T, Wang XW. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci 2011; 1:4; PMID:21711587; http://dx.doi.org/10.1186/2045-3701-1-4
39. Mansueto G, Forzati F, Ferraro A, Pallante P, Bianco M, Esposito F, et al. Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. Genes Cancer 2010; 1:210-24; PMID:21779448; http://dx.doi.org/10.1177/1947601910366860
40. Cuesta R, Martínez-Sánchez A, Gebauer F. miR-181a regulates cap-dependent translation of p27(kip1) mRNA in myeloid cells. Mol Cell Biol 2009; 29:2841-51; PMID:19273599; http://dx.doi.org/10.1128/MCB.01971-08
41. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 2011; 147:382-95; PMID:22000016; http://dx.doi.org/10.1016/j. cell.2011.09.032
42. Guha M. PARP inhibitors stumble in breast cancer. Nat Biotechnol 2011; 29:373-4; PMID:21552220; http://dx.doi.org/10.1038/nbt0511-373
43. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70:1793-803; PMID:20145152; http://dx.doi. org/10.1158/0008-5472.CAN-09- 3112
44. Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012; 18:2344-51; PMID:22371451; http://dx.doi.org/10.1158/1078-0432.CCR-11-2425
45. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28:1145-53; PMID:20100965; http://dx.doi. org/10.1200/JCO.2009.22.4725
46. Jiang J, Zheng X, Xu X, Zhou Q, Yan H, Zhang X, et al. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS ONE 2011; 6:e23271; PMID:21876743; http://dx.doi. org/10.1371/journal.pone.0023271
47. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, et al. Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics 2006; 3:317-24; PMID:18172508
48. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11:849-64; PMID:22113163; http://dx.doi.org/10.1038/nrc3166
49. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9:775-89; PMID:20885409; http://dx.doi.org/10.1038/nrd3179